Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 07-31-2019, 05:35 PM   #1
Senior Member
Join Date: Nov 2005
Posts: 338
Association between HER2 positivity by HER2/CEP17 ratio

I was rereading my wife's pathology report today and saw the Her2/Cep17 ratio. Too late for us, but might be of help to some.



Association between HER2 positivity by HER2/CEP17 ratio and response to neoadjuvant HER2 targeted therapy.
Katherine Cynthia Rappazzo, Heidi Chen, Tarah Jean Ballinger, Vandana Gupta Abramson
Show More

Abstract Disclosures



Background: Human epidermal growth factor receptor gene 2 (HER2) amplification status in breast cancers provides prognostic information and predicts response to HER2 targeted therapies. Breast cancers undergo HER2 testing by immunohistochemistry (IHC) or florescent in situ hybridization (FISH), with a positive result by dual-probe FISH if the HER2/CEP17 ratio is ≥ 2.0. Patients who are positive for HER2 amplification respond well to HER2 targeted therapies, but no correlation has been made between the quantitative level of HER/CEP17 ratio and tumor response. We aimed to determine whether increasing quantitative levels of HER2/CEP17 ratio lead to increasing rates of pathologic response to neoadjuvant HER2 targeted therapy.

Methods: Patients (n = 125) with locally advanced HER2+ breast cancer who received neoadjuvant HER2 targeted therapies including trastuzumab, pertuzumab, ado-trastuzumab, and lapatinib without cytotoxic chemotherapy were studied retrospectively. The HER2/CEP17 ratio at diagnosis was correlated to pathological complete response (pCR), residual tumor < 0.5cm (pCR0.5), and residual tumor < 1cm (pCR1) and adjusted for ER status.

Results: Data from 125 patients were analyzed. Using logistic regression, there was a statistically significant nonlinear association between HER2/CEP17 ratio and pCR ( p < 0.01). Increasing HER2/CEP17 ratio positively correlated with pCR from HER2/CEP17 ratios between 2 and 11. As HER2/CEP17 ratios increased to beyond 11, the curve had a slight downward concavity. The same pattern was seen for HER2/CEP17 ratio correlating with pCR0.5 (p = 0.0055), and pCR1 (p = 0.0126). ER status was not correlated to HER2 ratio using a Wilcoxon rank sum test with continuity correction (p = 0.8505).

Conclusions: Quantitative increases in HER2/CEP17 ratio are positively correlated to degree of pathologic response to neoadjuvant HER2 targeted therapies without cytotoxic chemotherapy for HER2/CEP17 ratios up to 11. Above HER2/CEP17 ratios of 11, response rates remain high, but do not have an additive benefit in response to HER2 targeted therapy.
Nguyen is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 04:53 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2021, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter